SEC Form 4 · accession 0001209191-16-088045
ARROWHEAD PHARMACEUTICALS, INC. · ARWR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David L. Lewis
Officer — Chief Scientific Officer
Period of report
Jan 1, 2016
Accepted (ET)
Jan 4, 2016 · 7:24 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000879407
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1 | $6.15 | Jan 1, 2016 | A | 85,000 | A | — | Jan 1, 2026 | Common Stock | 85,000 | 472,500 | D |
Explanation of responses
- F1Option vests and becomes exercisable over a four year period from date of grant.